Literature DB >> 28983645

[Pseudomonas aeruginosa infections in chronic obstructive pulmonary disease : Role of long-term antibiotic treatment].

G G U Rohde1, T Welte2.   

Abstract

Chronic Pseudomonas aeruginosa colonization in the airways of patients with chronic obstructive pulmonary disease (COPD) is probably associated with increased mortality and morbidity and a faster progress of COPD, although this has not been conclusively proven by studies. Studies demonstrating an improvement in prognosis in COPD patients by early eradication of Pseudomonas or at least a reduction of the bacterial burden by either inhaled or oral antibiotic maintenance therapy, are missing. An impact on the exacerbation rate has only been shown for macrolide maintenance treatment; however, this effect could be explained by the inclusion of patients with bronchiectasis in the studies. This is a group of patients for whom the effect of this kind of antibiotic treatment is well known. Further studies on the prevention and treatment of chronic Pseudomonas colonization in COPD patients are urgently needed. The stability of the respiratory microbiome probably plays an essential role in the course of the disease and should be established as a study endpoint.

Entities:  

Keywords:  Bronchiectasis; COPD; Macrolides; Pseudomonas aeruginosa; Therapy

Mesh:

Substances:

Year:  2017        PMID: 28983645     DOI: 10.1007/s00108-017-0332-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  32 in total

Review 1.  [Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].

Authors:  J Rademacher; M W Pletz; T Welte
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

2.  Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.

Authors:  Simon de Denus; Eileen O'Meara; Akshay S Desai; Brian Claggett; Eldrin F Lewis; Grégoire Leclair; Martin Jutras; Joël Lavoie; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Jean L Rouleau
Journal:  N Engl J Med       Date:  2017-04-27       Impact factor: 91.245

3.  Microbial airway colonization is associated with noninvasive ventilation failure in exacerbation of chronic obstructive pulmonary disease.

Authors:  Miquel Ferrer; Malina Ioanas; Francisco Arancibia; Maria Angeles Marco; Jorge Puig de la Bellacasa; Antoni Torres
Journal:  Crit Care Med       Date:  2005-09       Impact factor: 7.598

4.  Host Response to the Lung Microbiome in Chronic Obstructive Pulmonary Disease.

Authors:  Marc A Sze; Pedro A Dimitriu; Masaru Suzuki; John E McDonough; Josh D Campbell; John F Brothers; John R Erb-Downward; Gary B Huffnagle; Shizu Hayashi; W Mark Elliott; Joel Cooper; Don D Sin; Marc E Lenburg; Avrum Spira; William W Mohn; James C Hogg
Journal:  Am J Respir Crit Care Med       Date:  2015-08-15       Impact factor: 21.405

5.  Pseudomonas aeruginosa in chronic obstructive pulmonary disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Karen Eschberger; Phyllis Lobbins; Lori Grove; Xueya Cai; Sanjay Sethi
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

6.  Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD.

Authors:  M Miravitlles; A Marín; E Monsó; S Vilà; C de la Roza; R Hervás; C Esquinas; M García; L Millares; J Morera; A Torres
Journal:  Eur Respir J       Date:  2009-04-22       Impact factor: 16.671

7.  Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.

Authors:  Sevim Uzun; Remco S Djamin; Jan A J W Kluytmans; Paul G H Mulder; Nils E van't Veer; Anton A M Ermens; Aline J Pelle; Henk C Hoogsteden; Joachim G J V Aerts; Menno M van der Eerden
Journal:  Lancet Respir Med       Date:  2014-04-15       Impact factor: 30.700

8.  Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials.

Authors:  Li-Chao Fan; Hai-Wen Lu; Ping Wei; Xiao-Bin Ji; Shuo Liang; Jin-Fu Xu
Journal:  BMC Infect Dis       Date:  2015-03-27       Impact factor: 3.090

9.  Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.

Authors:  Sanjay Sethi; Paul W Jones; Marlize Schmitt Theron; Marc Miravitlles; Ethan Rubinstein; Jadwiga A Wedzicha; Robert Wilson
Journal:  Respir Res       Date:  2010-01-28

10.  Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

Authors:  David J Serisier; Diana Bilton; Anthony De Soyza; Philip J Thompson; John Kolbe; Hugh W Greville; David Cipolla; Paul Bruinenberg; Igor Gonda
Journal:  Thorax       Date:  2013-05-16       Impact factor: 9.139

View more
  3 in total

1.  Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.

Authors:  Elena K Schneider-Futschik; Olivia K A Paulin; Daniel Hoyer; Kade D Roberts; James Ziogas; Mark A Baker; John Karas; Jian Li; Tony Velkov
Journal:  ACS Infect Dis       Date:  2018-04-02       Impact factor: 5.084

Review 2.  Emerging therapies against infections with Pseudomonas aeruginosa.

Authors:  Burkhard Tümmler
Journal:  F1000Res       Date:  2019-08-07

3.  Phenotypic and Genomic Comparison of the Two Most Common ExoU-Positive Pseudomonas aeruginosa Clones, PA14 and ST235.

Authors:  Sebastian Fischer; Sarah Dethlefsen; Jens Klockgether; Burkhard Tümmler
Journal:  mSystems       Date:  2020-12-08       Impact factor: 6.496

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.